Skip to main content
SpringerLink
Log in

Further support for use of thrombopoietins in cancer

  • Newsletter Article
  • Published:
Inpharma Weekly

Abstract

The results of a recent study of Amgen’s PEG-thrombopoietin [PEG-MGDF * ] have confirmed the efficacy of this agent in terms of reducing the severity and duration of thrombocytopenia in patients with cancer. The study results are a positive step in the development of Amgen’s thrombopoietin product. However, specialists in the field believe that Genentech’s recombinant human thrombopoietin [MGDF] is similarly effective. The 2 agents were discussed at the 4th International Congress on Biological Response Modifiers [ San Antonio, US; March 1997 ].

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Authors
  1. Robert Carlson
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

* PEG-thrombopoietin = pegylated megakaryocyte growth and development factor; Amgen; phase II

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carlson, R. Further support for use of thrombopoietins in cancer. Inpharma Wkly. 1083, 9–10 (1997). https://doi.org/10.2165/00128413-199710830-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199710830-00014

Keywords

Search

Navigation